Interleukin-2
From NKcells.info
Contents |
Introduction
IL-2 and NK cells
Interleukin-2 (IL-2) is the major cytokine used for activation of Natural Killer cells.
Gays et al. (2005, [1]) demonstrated that IL-2 (and IL-15) selectively induced the de novo expression of Ly49E on murine mature NK cells.
Chrul et al. (2006, PMID:17047292) demonstrated that stimulation of NK cells by a mixture of IL-12 and IL-18 caused a significant increase in KIR2DL1+ and KIR2DL2+ NK cells but not in KIR3DL2+ cells, while stimulation with IL-2 increased the frequency of all three subsets.
Chiossone et al. (2007, PMID:17234744 suggest a different ability of IL-15-cultured NK cells compared to IL-2-cultured NK cells to survive to steroid treatment. This may have an impact for a correct NK cells cytokine conditioning in adoptive immunotherapy.
IL-2 @ COPE
Publications
2007
Chiossone L, Vitale C, Cottalasso F, Moretti S, Azzarone B, Moretta L, Mingari MC.
Molecular analysis of the methylprednisolone-mediated inhibition of NK cell function: evidence for different susceptibility of IL-2-versus IL-15-activated NK cells.
Blood. 2007 Jan 18;. Epub, PMID:17234744
2006
McFarlin BK, Flynn MG, Hampton T.
Carbohydrate consumption during cycling increases in vitro NK cell responses to IL-2 and IFN-gamma.
Brain Behav Immun. 2006 Aug 2;. Epub, PMID:16889932
2005
Ozdemir O, Savasan S.
Combinational IL-2/IL-15 induction does not further enhance IL-15-induced lymphokine-activated killer cell cytotoxicity against human leukemia/lymphoma cells.
Clin Immunol. 2005 Jun;115(3):240-249. PMID: 15893691
Kerst JM, Bex A, Mallo H, Dewit L, Haanen JB, Boogerd W, Teertstra HJ, de Gast GC.
Prolonged low dose IL-2 and thalidomide in progressive metastatic renal cell carcinoma with concurrent radiotherapy to bone and/or soft tissue metastasis: a phase II study.
Cancer Immunol Immunother. 2005 May 19;. Epub PMID: 15906025
Konstantinidis KV, Alici E, Aints A, Christensson B, Ljunggren HG, Dilber MS.
Targeting IL-2 to the endoplasmic reticulum confines autocrine growth stimulation to NK-92 cells.
Exp Hematol. 2005 Feb;33(2):159-64. PMID: 15676209
Kerst JM, Bex A, Mallo H, Dewit L, Haanen JB, Boogerd W, Teertstra HJ, de Gast GC.
Prolonged low dose IL-2 and thalidomide in progressive metastatic renal cell carcinoma with concurrent radiotherapy to bone and/or soft tissue metastasis: a phase II study.
Cancer Immunol Immunother. 2005 May 19;. Epub PMID: 15906025
Brief report: IL-15 but not IL-2 rapidly induces lethal xenogeneic graft-versus-host disease
S. Roychowdhury, B. W. Blaser, A. G. Freud, K. Katz, D. Bhatt, A. K. Ferketich, V. Bergdall, D. Kusewitt, R. A. Baiocchi, and M. A. Caligiuri
Blood 2005 106 (7)
2002
Vitale M, Bassini A, Secchiero P, Mirandola P, Ponti C, Zamai L, Mariani AR, Falconi M, Azzali G.
NK-active cytokines IL-2, IL-12, and IL-15 selectively modulate specific protein kinase C (PKC) isoforms in primary human NK cells.
Anat Rec. 2002 Feb 1;266(2):87-92. PMID: 11788941
IL-2 @ WikiPedia
Interleukin-2 (IL-2) is an interleukin, a type of biological response modifier, a substance that can improve the body's natural response to disease.
IL-2 is normally produced by the body, secreted by WikiPedia:T cells, and stimulates growth and differentiation of T cell response. It can be used in immunotherapy to treat cancer. It enhances the ability of the immune system to kill tumor cells and may interfere with blood flow to the tumor.
Aldesleukin (Proleukin®, ATC code L03AC01) is WikiPedia:recombinant IL-2 used in treating WikiPedia:malignant melanoma and WikiPedia:renal cell carcinoma.
